DPP-4 inhibition improves cardiac function in experimental myocardial infarction: Role of SDF-1 alpha BACKGROUND: In addition to degrading glucagon-like peptide-1, di-peptidyl peptidase 4 (DPP-4) inactivates several chemokines. Among these is stromal derive... KA Connelly,A Advani,Y Zhang,......
Gut hormones orchestrate pivotal physiological processes in multiple metabolically active tissues, including the pancreas, liver, adipose tissue, gut and central nervous system, making them attractive therapeutic targets in the treatment of obesity and t
Catherine J. Field1, David Berry4,7, Carla M. Prado1 and Jens Walter1,15,16* Abstract Background: Dietary fiber is an integral part of a healthy diet, but questions remain about the mechanisms that underlie effects and the causal contributions of the gut ...
Scalable ruthenium-catalyzed asymmetric synthesis of a key intermediate for the β2-Adrenergic receptor agonist. Org. Process Res. Dev. 19, 315–319 (2015). Article CAS Google Scholar Chung, J. Y. L. et al. Evolution of a manufacturing route to omarigliptin, a long-acting DPP-4 ...
The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has profoundly impacted global healthcare systems and spurred extensive research efforts over the past three years. One critical aspect of the disease is the intricate interplay between the virus and the host immune response, part...
Multiple sclerosis (MS) is the most frequent inflammatory and demyelinating disease of the central nervous system (CNS). The underlying pathophysiology of MS is the destruction of myelin sheath by immune cells. The formation of myelin plaques, inflammati
The Cyclin-dependent kinase (CDK) class of serine/threonine kinases has crucial roles in the regulation of cell cycle transition and is mainly involved in the pathogenesis of cancers. The expression of CDKs is controlled by a complex regulatory network c
Heart failure with preserved ejection fraction (HFpEF) is a prevalent and complex condition with limited effective treatments. Endothelial dysfunction is a significant component of HFpEF pathophysiology, and glucagon-like peptide-1 receptor (GLP-1R) agon
(DPP-4). GLP-1RAs activate GLP-1R similarly to GLP-1, but they are resistant to the activity of DPP-4. Ultimately, GLP-1RAs enhance insulin excretion, leading to the inhibition of glucagon production by pancreatic α-cells when blood sugar levels are high as well as a decrease of ...
It was not until the serendipitous finding that exendin-4 from the saliva of the Gila monster was both an agonist of the human GLP-1R and resistant to degradation by dipeptidyl peptidase-4 (DPP-4) that the therapeutic potential of GLP-1R activation could be clinically exploited.2 Thus, ...